Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 13, Number 7—July 2007

Research

Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom

Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†Comments to Author 
Author affiliations: *McGill University Health Center, Montreal, Quebec, Canada; †Royal Victoria Hospital, Montreal, Quebec, Canada; ‡Sir Mortimer B. Davis–Jewish General Hospital, Montreal, Quebec, Canada;

Main Article

Table 2

Risk for infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA)*

No. prescriptions of antimicrobial drugs Case-patients
(N = 1,981), no. (%) Control-patients
(N = 19,779), no. (%) Crude OR Adjusted OR† 95% CI
0 (reference) 770 (38.9) 12,821 (64.8) 1 1
>1 1,211 (61.1) 6,958 (35.2) 2.98 2.61 2.36–2.89
1 328 (16.6) 3,306 (16.7) 1.69 1.57 1.36–1.80
2 or 3 373 (18.8) 2,389 (12.1) 2.73 2.46 2.15–2.83
>4 510 (25.7) 1,263 (6.4) 7.27 6.24 5.43–7.17

*For persons prescribed <1 antimicrobial drug in the 30–365 days before their index date, relative to risk for MRSA infection in persons with no prescriptions during the same period. Data from General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, confidence interval.
†Adjusted for all variables in Table 1.

Main Article

TOP